DORAL, Fla. / Jul 18, 2024 / Business Wire / NeueHealth, Inc. ("NeueHealth") (NYSE: NEUE), the value-driven healthcare company, today announced it will report Second Quarter financial results before the financial markets open on Wednesday, August 7, 2024, followed by a conference call at 8:00 AM Eastern Time.
To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call.
A webcast of the earnings call may also be accessed via NeueHealth’s Investor Relations page at investors.neuehealth.com. The company suggests participants for the conference call dial in at least 15 minutes in advance of the call. A recording of the earnings call and presentation will be available on NeueHealth’s Investor Relations page following the call.
About NeueHealth
NeueHealth is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. NeueHealth delivers high-quality clinical care to over 500,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers. We also enable independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally. We believe our value-driven, consumer-centric care model can transform the healthcare experience and maximize value across the healthcare ecosystem. For more information, visit: www.neuehealth.com.
Last Trade: | US$5.14 |
Daily Change: | 0.09 1.78 |
Daily Volume: | 9,196 |
Market Cap: | US$42.560M |
October 30, 2024 August 07, 2024 May 08, 2024 March 06, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB